Pleuro-peritoneal communication in a patient on dialysis @TheLancetTV

Pleuro-peritoneal communication in a patient on dialysis @TheLancetTV

The Lancet | Pleuro-peritoneal communication in a patient on dialysis @TheLancetTV | Uploaded September 2022 | Updated October 2024, 5 hours ago.
Read the full Clinical Picture, A sweet unilateral pleural effusion: pleuro-peritoneal communication in a patient on dialysis, in The Lancet: thelancet.com/journals/lancet/article/PIIS0140-6736(22)01329-0/fulltext?dgcid=youtube_video_lancet_clinpic

Visit The Lancet at thelancet.com/?dgcid=youtube_video_lancet_clinpic

* * *
Continue this conversation on social! Follow us today at…
Twitter.com/TheLancet
Facebook.com/TheLancetMedicalJournal
Instagram.com/TheLancetGroup
LinkedIn.com/company/The-Lancet

Pleuro-peritoneal communication in a patient on dialysis

Advancements in Non-Small Cell Lung Cancer

How to improve access to diagnostics for everyone | The Lancet Commission (BSL-interpreted)

Lancet Countdown 2020: Global launch

What is The Lancet? (BSL-interpreted)

Vertebral artery halo sign in giant cell arteritis

COVID-19 mRNA vaccine-related adenopathy mimicking metastatic melanoma

$Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer Dr James Harding presents the findings of their paper, published in The Lancet Oncology on 2 June 2023: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZONBTC-01): a multicentre, single-arm, phase 2b study. Read the full article here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00242-5/fulltext?dgcid=youtube_video_tlo HER2 is overexpressed or amplified in a subset of biliary tract cancer. Zanidatamab is a bispecific antibody targeting two distinct HER2 epitopes. The results from the study show that Zanidatamab has meaningful clinical benefit with a manageable safety profile in patients with treatment-refractory, HER2-positive biliary tract cancer, supporting its potential use as a future treatment option in HER2-positive biliary tract cancer. Visit The Lancet Oncology at https://www.thelancet.com/journals/lanonc/home?dgcid=youtube_video_tlo Find out more at https://www.thelancet.com/?dgcid=youtube_video_lancet_lancet * * * Continue this conversation on social! Follow us today at… https://Twitter.com/TheLancet & https://Twitter.com/TheLancetOncol https://Instagram.com/thelancetgroup https://Facebook.com/TheLancetMedicalJournal https://LinkedIn.com/company/the-lancet$

The Lancet Commission on medicine, Nazism, and the Holocaust | Global launch event

Always use containment morcellation bags

The Lancet Countdown on Health and Climate Change: 2023 Global Launch Event

Hyperparathyroidism shows its hand: findings of osteitis fibrosa cystica

🔇 TAP TO UNMUTE

Pleuro-peritoneal communication in a patient on dialysis @TheLancetTV